Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Allison Kennedy

Physician Assistant Fullerton, CA Physician Assistant

NPI 1265840987 CMS profile 10692300

100 Laguna Rd Ste 208, Fullerton, CA 92835

Open in the dashboard

General payments

$53,834

530 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Allison Kennedy of Fullerton, CA is reported in the CMS Open Payments database as having received $53,834 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $50 1
2023 General $14,258 123
2022 General $19,540 221
2021 General $19,986 185

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Kennedy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Allison Kennedy were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Allison Kennedy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $19,986 $132 $37–$438 $132
2022 $19,540 $155 $48–$522 $149
2023 $14,258 $167 $52–$557 $160
2024 $50 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $29,671 147 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $5,249 28 payments
  3. Biohaven Pharmaceuticals, Inc. $4,225 20 payments
  4. Alexion Pharmaceuticals, Inc. $3,762 20 payments
  5. Teva Pharmaceuticals USA, Inc. $1,679 8 payments
  6. Allergan Inc. $1,585 23 payments
  7. Medtronic, Inc. $1,134 12 payments
  8. Novartis Pharmaceuticals Corporation $928 57 payments
  9. Biogen, Inc. $797 31 payments
  10. SK Life Science, Inc. $493 18 payments
  11. Other $4,311 166 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,197 27 payments
  2. Food and Beverage $12,593 480 payments
  3. Consulting Fee $3,710 2 payments
  4. Travel and Lodging $3,314 15 payments
  5. Education $19 6 payments
Products named General payments · program years 2021–2024
  1. UBRELVY $28,435 70 payments
  2. QULIPTA $13,376 57 payments
  3. NURTEC ODT $9,473 48 payments
  4. ULTOMIRIS $3,435 14 payments
  5. AJOVY $1,679 8 payments
  6. PERCEPT PC BRAINSENSE $1,112 11 payments
  7. KESIMPTA $733 47 payments
  8. BOTOX $634 34 payments
  9. VUMERITY $585 22 payments
  10. TYSABRI $559 21 payments
  11. Other $5,957 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

79

Median for Physician Assistant: 241

Drug cost

$2,219

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 18 $638
Sumatriptan Succinate Generic 12 $607
Carbidopa-Levodopa Carbidopa/Levodopa Brand 14 $468
Donepezil Hcl Generic 11 $213
Gabapentin Generic 12 $150
Duloxetine Hcl Generic 12 $143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record